The demo achieved both equally its Major endpoints, with semaglutide 2.four mg demonstrating statistically major and exceptional improvements in liver fibrosis without having worsening of steatohepatitis, in addition to resolution of steatohepatitis without worsening of liver fibrosis in individuals with MASH as compared to placebo.1Preserve all ap